Source: Eur Respir J, 53 (6) 1900583; 10.1183/13993003.00583-2019
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Anne L. Theilmann, Mark L. Ormiston. Repurposing benzbromarone for pulmonary arterial hypertension: can channelling the past deliver the therapy of the future?. Eur Respir J, 53 (6) 1900583; 10.1183/13993003.00583-2019

Member's Comments

No comment yet.

Related content which might interest you: Goal-oriented therapy in paediatric pulmonary arterial hypertension: are we ready? Source: Eur Respir J 2014; 44: 1404-1407 Year: 2014 Pulmonary arterial hypertension: combination therapy in the modern management era Source: Eur Respir Rev 2010 19: 348-349 Year: 2010 Pulmonary arterial hypertension: tailoring treatment to risk in the current era Source: Eur Respir Rev, 26 (146) 170095; 10.1183/16000617.0095-2017 Year: 2017 Pulmonary arterial hypertension registries: past, present and into the future Source: Eur Respir Rev, 28 (154) 190128; 10.1183/16000617.0128-2019 Year: 2019 Challenging the concept of adding more drugs in pulmonary arterial hypertension Source: Eur Respir J, 50 (3) 1701527; 10.1183/13993003.01527-2017 Year: 2017 Novel therapeutic perspectives in pulmonary arterial hypertension Source: Eur Respir J 2003; 22: 193-194 Year: 2003 The future of treatment for pulmonary arterial hypertension Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017 The future of treatment for pulmonary arterial hypertension Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2014 The future of treatment for pulmonary arterial hypertension Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease Year: 2012 The future of treatment for pulmonary arterial hypertension Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018 Challenges in the diagnosis and treatment of pulmonary arterial hypertension Source: Eur Respir Rev 2012 21: 313-320 Year: 2012 Lessons learned from trials of anti-remodelling drugs in pulmonary arterial hypertension Source: International Congress 2019 – State of the art session: Pulmonary vascular diseases Year: 2019 Physicians’ and patients’ expectations of therapies for pulmonary arterial hypertension: where do they meet? Source: Eur Respir Rev 2014; 23: 458-468 Year: 2014 Initial triple therapy in pulmonary arterial hypertension: coming of age and rejuvenated Source: Eur Respir J, 57 (1) 2004258; 10.1183/13993003.04258-2020 Year: 2021 The role of combination therapy in managing pulmonary arterial hypertension Source: Eur Respir Rev 2014; 23: 469-475 Year: 2014 Current medical treatment of pulmonary arterial hypertension Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018 Current medical treatment of pulmonary arterial hypertension Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017